Abstract
Polyphasic sleep is the practice of distributing multiple short sleep episodes across the 24-hour day rather than having one major and possibly a minor (“nap”) sleep episode each day. While the prevalence of polyphasic sleep is unknown, anecdotal reports suggest attempts to follow this practice are common, particularly among young adults. Polyphasic-sleep advocates claim to thrive on as little as 2 hours of total sleep per day. However, significant concerns have been raised that polyphasic sleep schedules can result in health and safety consequences. We reviewed the literature to identify the impact of polyphasic sleep schedules (excluding nap or siesta schedules) on health, safety, and performance outcomes. Of 40,672 potentially relevant publications, with 2,023 selected for full-text review, 22 relevant papers were retained. We found no evidence supporting benefits from following polyphasic sleep schedules. Based on the current evidence, the consensus opinion is that polyphasic sleep schedules, and the sleep deficiency inherent in those schedules, are associated with a variety of adverse physical health, mental health, and performance outcomes. Striving to adopt a schedule that significantly reduces the amount of sleep per 24 hours and/or fragments sleep into multiple episodes throughout the 24-hour day is not recommended.
Original language | English (US) |
---|---|
Pages (from-to) | 293-302 |
Number of pages | 10 |
Journal | Sleep Health |
Volume | 7 |
Issue number | 3 |
DOIs | |
State | Published - Jun 2021 |
Keywords
- Circadian misalignment
- Health
- Performance
- Polyphasic sleep
- Sleep patterns
ASJC Scopus subject areas
- Health(social science)
- Neuropsychology and Physiological Psychology
- Social Sciences (miscellaneous)
- Behavioral Neuroscience
Fingerprint
Dive into the research topics of 'Adverse impact of polyphasic sleep patterns in humans: Report of the National Sleep Foundation sleep timing and variability consensus panel'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Sleep Health, Vol. 7, No. 3, 06.2021, p. 293-302.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Adverse impact of polyphasic sleep patterns in humans
T2 - Report of the National Sleep Foundation sleep timing and variability consensus panel
AU - Weaver, Matthew D.
AU - Sletten, Tracey L.
AU - Foster, Russell G.
AU - Gozal, David
AU - Klerman, Elizabeth B.
AU - Rajaratnam, Shantha M.W.
AU - Roenneberg, Till
AU - Takahashi, Joseph S.
AU - Turek, Fred W.
AU - Vitiello, Michael V.
AU - Young, Michael W.
AU - Czeisler, Charles A.
N1 - Funding Information: Dr. Klerman reports personal (consulting) fees from Wellesley College, CQ University (Australia), Puerto Rico Science Technology and Research Trust, the National Sleep FoundationPfizer, and Sanofi-Genzyme; non-financial (ttravel and registration) support from the Sleep Research Society, Santa Fe Institute, UT Austin, World Conference of Chronobiology, Gordon Research Conference, Stanford University, Northwestern University Solvay Institute (Belgium), Catholic University (Portugal);and personal fees and non-financial support from LMU (Germany), and NIH. All these are outside the submitted work. Dr. Klerman reports non-financial (travel) support from the National Sleep Foundation related to the submitted work. Funding Information: This project was supported by the National Sleep Foundation. The National Sleep Foundation had no role in the preparation of the manuscript or the decision to publish. Dr. Takahashi is an investigator in the Howard Hughes Medical Institute. Dr. Czeisler reports grants to BWH from NHLBI, NIA, NIOSH, and DOD, and serves as the incumbent of an endowed professorship provided to Harvard University by Cephalon, Inc. Dr. Klerman reports grants from NIH, the FAA, and salary support from Harvard University and the Massachusetts Institute of Technology during the conduct of the study. Funding Information: Dr. Turek reports personal fees from Nature's Bounty Board of Advisers and grants from Vanda Pharmaceuticals, outside the submitted work. Funding Information: Dr. Weaver reports grants from the Brigham Research Institute, NHLBI and NIOSH, and personal fees from University of Pittsburgh, outside the submitted work. Funding Information: We are grateful for logistical support and coordination from Katherine Draghi, Meredith Ellison, Anita Roach, and the National Sleep Foundation. We also thank Bryan Baxter, Lauren Booker, Ivy Mason, Megan Mulhall, Rebecca Robbins, and Melissa St. Hilaire for assistance with the literature review. Dr. Weaver reports grants from the Brigham Research Institute, NHLBI and NIOSH, and personal fees from University of Pittsburgh, outside the submitted work. Dr. Weaver and Dr. Sletten report personal fees from the National Sleep Foundation during the conduct of the study. Dr. Klerman reports personal (consulting) fees from Wellesley College, CQ University (Australia), Puerto Rico Science Technology and Research Trust, the National Sleep FoundationPfizer, and Sanofi-Genzyme; non-financial (ttravel and registration) support from the Sleep Research Society, Santa Fe Institute, UT Austin, World Conference of Chronobiology, Gordon Research Conference, Stanford University, Northwestern University Solvay Institute (Belgium), Catholic University (Portugal);and personal fees and non-financial support from LMU (Germany), and NIH. All these are outside the submitted work. Dr. Klerman reports non-financial (travel) support from the National Sleep Foundation related to the submitted work. Dr. Rajaratnam reports positions as the Program Leader for the CRC for Alertness, Safety and Productivity, Australia and the Director of the Sleep Health Foundation. He received grants from Vanda Pharmaceuticals, Philips Respironics, Cephalon, Rio Tinto, BHP Billiton and Shell which are not related to this paper. He also received equipment support and consultancy fees through his institution from Optalert, Compumedics, Teva Pharmaceuticals, and Circadian Therapeutics, which are not related to this paper. Dr. Roenneberg is the founder and Chief Scientific Officer of the company Chronsulting UG and consults several other companies (Vanda Pharmaceuticals, Chiesi GmbH, jetlite GmbH, Condor Instruments, Salzgitter AG; PricewaterhouseCoopers; Weightwatchers; KGK Science Inc.); none of these activities created conflicts with the content of this paper. Dr. Takahashi's conflicts of interest are all outside the submitted work. He is a co-founder and SAB member of Synchronicity Pharma, Inc. Dr. Turek reports personal fees from Nature's Bounty Board of Advisers and grants from Vanda Pharmaceuticals, outside the submitted work. Dr. Czeisler's conflicts of interest are all outside the submitted work. They include institutional gifts from: Mary Ann & Stanley Snider via Combined Jewish Philanthropies, Optum, Philips Respironics Inc, ResMed Foundation, San Francisco Bar Pilots, Sanofi SA, Sysco Corp, and Teva Pharmaceuticals Industries Ltd; and gifts and grants from Jazz Pharmaceuticals Plc Inc; and grants from Regeneron Pharmaceuticals, and Dayzz Ltd. They include personal fees from Bose Corporation, Boston Red Sox, Columbia River Bar Pilots, Institute of Digital Media and Child Development, Klarman Family Foundation, Samsung Electronics, Zurich Insurance Company Ltd, Washington State Board of Pilotage Commissioners, Gan?sco Inc, Teva Pharma Australia, AARP, M. Davis and Company, Physician's Seal, United States Aircraft Insurance Group, National Sleep Foundation, Sleep Research Society, and Tencent; and non-financial support from Boston Celtics, CurtCo Media Labs LLC, Schneider Inc; and personal fees and an equity interest in Vanda Pharmaceuticals Inc. Dr. Czeisler is the incumbent of an endowed professorship provided to Harvard University by Cephalon, Inc. In addition, Dr. Czeisler receives royalty income from McGraw Hill, the New England Journal of Medicine, and Philips Respironics for the Actiwatch-2 and Actiwatch-Spectrum devices. Dr. Czeisler has served as an expert witness on a number of civil matters, criminal matters, and arbitration cases, including those involving the following commercial and government entities: Advanced Power Technologies; Alvarado Hospital, LLC; Amtrak; Bombardier, Inc.; C&J Energy Services; Casper Sleep, Inc.; Columbia River Bar Pilots; Complete General Construction Company; Dallas Police Department; Delta Airlines/Comair; F?d?ration des M?decins R?sidents du Qu?bec (FMRQ); FedEx; Greyhound Lines, Inc./Motor Coach Industries/FirstGroup America; H.G. Energy LLC; Maricopa County, Arizona, Sheriff's Office; Murrieta Valley Unified School District; Pomerado Hospital, Palomar Health District; Puckett EMS; Purdue Pharma; South Carolina Central Railroad Company, LLC.; Steel Warehouse, Inc.; Union Pacific Railroad; United Parcel Service. Dr. Czeisler served as a voluntary board member for the Institute for Experimental Psychiatry Research Foundation, Inc. Dr. Czeisler's interests were reviewed and managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies. Dr. Foster, Dr. Gozal, Dr. Vitiello, and Dr. Young report no conflicts to declare. Publisher Copyright: © 2021 The Authors
PY - 2021/6
Y1 - 2021/6
N2 - Polyphasic sleep is the practice of distributing multiple short sleep episodes across the 24-hour day rather than having one major and possibly a minor (“nap”) sleep episode each day. While the prevalence of polyphasic sleep is unknown, anecdotal reports suggest attempts to follow this practice are common, particularly among young adults. Polyphasic-sleep advocates claim to thrive on as little as 2 hours of total sleep per day. However, significant concerns have been raised that polyphasic sleep schedules can result in health and safety consequences. We reviewed the literature to identify the impact of polyphasic sleep schedules (excluding nap or siesta schedules) on health, safety, and performance outcomes. Of 40,672 potentially relevant publications, with 2,023 selected for full-text review, 22 relevant papers were retained. We found no evidence supporting benefits from following polyphasic sleep schedules. Based on the current evidence, the consensus opinion is that polyphasic sleep schedules, and the sleep deficiency inherent in those schedules, are associated with a variety of adverse physical health, mental health, and performance outcomes. Striving to adopt a schedule that significantly reduces the amount of sleep per 24 hours and/or fragments sleep into multiple episodes throughout the 24-hour day is not recommended.
AB - Polyphasic sleep is the practice of distributing multiple short sleep episodes across the 24-hour day rather than having one major and possibly a minor (“nap”) sleep episode each day. While the prevalence of polyphasic sleep is unknown, anecdotal reports suggest attempts to follow this practice are common, particularly among young adults. Polyphasic-sleep advocates claim to thrive on as little as 2 hours of total sleep per day. However, significant concerns have been raised that polyphasic sleep schedules can result in health and safety consequences. We reviewed the literature to identify the impact of polyphasic sleep schedules (excluding nap or siesta schedules) on health, safety, and performance outcomes. Of 40,672 potentially relevant publications, with 2,023 selected for full-text review, 22 relevant papers were retained. We found no evidence supporting benefits from following polyphasic sleep schedules. Based on the current evidence, the consensus opinion is that polyphasic sleep schedules, and the sleep deficiency inherent in those schedules, are associated with a variety of adverse physical health, mental health, and performance outcomes. Striving to adopt a schedule that significantly reduces the amount of sleep per 24 hours and/or fragments sleep into multiple episodes throughout the 24-hour day is not recommended.
KW - Circadian misalignment
KW - Health
KW - Performance
KW - Polyphasic sleep
KW - Sleep patterns
UR - http://www.scopus.com/inward/record.url?scp=85104944089&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104944089&partnerID=8YFLogxK
U2 - 10.1016/j.sleh.2021.02.009
DO - 10.1016/j.sleh.2021.02.009
M3 - Article
C2 - 33795195
AN - SCOPUS:85104944089
SN - 2352-7218
VL - 7
SP - 293
EP - 302
JO - Sleep Health
JF - Sleep Health
IS - 3
ER -